97270 ⎘
Immunoglobulins specific features characterized by post-translational modification Glycosylation, sialylation, or fucosylation
Fc-Containing Molecules Exhibiting Predictable, Consistent, and Reproducible Glycoform Profiles
#302GLYCOSYLATED ANTIBODIES
#303PRODUCTION OF HETERODIMERIC PROTEINS
#304Polynucleotides encoding antibodies which bind the EC3 domain of cadherin-6 (CDH6) and possess internalization ability
#305HUMANIZED ANTIBODIES DIRECTED AGAINST KCNK9
#306TRISPECIFIC ANTIBODIES SPECIFIC FOR HER2 AND A BLOOD BRAIN BARRIER RECEPTOR AND METHODS OF USE
#307ANTI-CD3 ANTIBODIES AND USES THEREOF
#308Antibody neutralizing human respiratory syncytial virus
#309ANTI-CTLA-4 MONOCLONAL ANTIBODY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
#310Antibodies Against IL-1 Beta
#311DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODY
#312DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODIES
#313Methods for increasing mannose content of recombinant proteins
#314Preparation and Purification of Hypersialylated IGG
#315HYPER-SIALYLATED IMMUNOGLOBULIN
#316ANTIBODY AND PROTEIN FORMULATIONS
#317FC VARIANT AND PREPARATION THEREOF
#318ANTIBODIES THAT BIND TO LRP5 PROTEINS AND METHODS OF USE
#319METHODS OF ADMINISTERING ANTI-OX40 ANTIBODIES
#320PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN
#321METHODS OF TREATING IMMUNE MEDIATED PULMONARY INJURY
#322ANTI-PD-L1 ANTIBODY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
#323ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA Fc GAMMA RIIB
#324Anti-MUC1 antibody-drug conjugate
#325ANTIGEN BINDING PROTEINS
#326Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
#327TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF
#328Bispecific antigen binding constructs targeting HER2
#329METHODS OF ADMINISTERING ANTI-OX40 ANTIBODIES
#330Antibody specific to spike protein of SARS-CoV-2 and uses thereof
#331Early Detection Of Hepatocellular Carcinoma
#332NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS
#333Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a β(1,4)-n-acetylgalactosaminyltransferase
#334ORIENTED AND COVALENT METHOD FOR IMMOBILIZING GLYCOPROTEIN AND ANTIBODY CHIP
#335Fc variant with enhanced affinity to Fc receptors and improved thermal stability
#336OPTIMIZED ANTI-CD3 ARM IN THE GENERATION OF T-CELL BISPECIFIC ANTIBODIES FOR IMMUNOTHERAPY
#337USE OF FUCOSYLATION INHIBITOR FOR PRODUCING AFUCOSYLATED ANTIBODY
#338MULTISPECIFIC ANTIBODIES
#339Glycosylated Single Chain Immunoglobulin Domains
#340HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)
#341Treatment of Ocular Diseases with Fully-Human Post-Translationally Modified Anti-VEGF Fab
#342NOVEL ANTI-FGFR2B ANTIBODIES
#343NOVEL ANTI-FGFR2B ANTIBODIES
#344Anti-TIGIT Antibodies
#345GLYCOSYLATED POLYPEPTIDES
#346Structures for Reducing Antibody-Lipase Binding
#347Anti-CCR8 antibodies
#348Pertuzumab variants and evaluation thereof
#349POPULATION OF ANTIBODIES COMPRISING HOMOGENEOUS ANTIBODIES EACH HAVING LEFT-RIGHT ASYMMETRIC SUGAR CHAINS, AND METHOD FOR PRODUCING SAME
#350HUMANIZED CLDN18.2 ANTIBODIES
#351Nucleic acids encoding and methods of producing proteins comprising antibody chains
#352ANTIBODIES TARGETING, AND OTHER MODULATORS OF, THE CD276 ANTIGEN, AND USES THEREOF
#353ANTIBODY VARIANT COMBINATIONS AND USES THEREOF
#354Antibodies that bind to OX40 and their uses
#355ANTI-CLL1 ANTIBODY AND USE THEREOF
#356BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3
#357METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN
#358GLYCOPEPTIDE ANALOGS OF SECRETIN FAMILY PEPTIDES
#359GLYCOFORM PURIFICATION
#360METHOD FOR INCREASING THE GALACTOSE CONTENT OF RECOMBINANT PROTEINS
#361Optimized crosslinkers for trapping a target on a substrate
#362METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS
#363Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof
#364MULTISPECIFIC ANTIBODIES
#365Methods of treatment using CCR8 antibodies
#366Polyomavirus neutralizing antibodies
#367ANTI-BCMA ANTIBODY CONJUGATES
#368Method for Producing Spesolimab
#369Frizzled receptor antibodies and uses thereof
#370ANTIBODIES SPECIFIC TO GLYCOSYLATED LAG3 AND METHODS OF USE THEREOF
#371METHODS OF PRODUCING ANTIBODY COMPOSITIONS
#372AGLYCOSYLATED ANTIBODY Fc REGION FOR TREATING CANCER
#373ANTI-SIGLEC-8 ANTIBODIES AND METHODS OF USE THEREOF
#374SSEA-4 BINDING MEMBERS
#375ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SUGAR CHAIN RECEPTOR-BINDING DOMAIN
#376FC-RECEPTOR BINDING MODIFIED ASYMMETRIC ANTIBODIES AND METHODS OF USE
#377GLYCOSYLATED IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#378Copper supplementation for control of glycosylation in mammalian cell culture process
#379IGM GLYCOVARIANTS
#380Therapeutic binding molecules
#381PLANT-PRODUCED mABs AGAINST CHIKUNGUNYA VIRUS WITH ENHANCED EFFECTOR FUNCTION AND EFFICACY
#382Protease deficient filamentous fungal cells and methods of use thereof
#383METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN
#384Anti-FAP antibodies and methods of use
#385TREATMENT OF DIABETIC RETINOPATHY WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB
#386BENEFICIAL BACTERIA AND SECRETORY IMMUNOGLOBULIN A
#387ANTIBODIES SPECIFIC TO GLYCOSYLATED PD-L1 AND METHODS OF USE THEREOF
#388Antibody compositions for disrupting biofilms
#389FCRN ANTAGONISTS AND METHODS OF USE
#390COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
#391ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
#392Antibodies to human complement factor C2B and methods of use
#393Methods for the treatment of neurodegeneration
#394SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAME
#395DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODY
#396BISPECIFIC ANTIBODY BINDING TO CD40 AND FAP
#397BISPECIFIC ANTIBODIES SPECIFIC FOR PD1 AND TIM3
#398Anti-LAG3 antibodies and antigen-binding fragments
#399BISPECIFIC BINDING PROTEINS AND USES THEREOF
#400DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODIES
#401NOVEL IMMUNOCONJUGATES
#402GLYCAN-BASED ANTIBODY-DRUG CONJUGATES
#403Anti-polyubiquitin multispecific antibodies
#404Anti-TEM1 antibodies and antigen-binding portions thereof
#405Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics
#406T cell activating bispecific antigen binding molecules
#407METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS
#408O-Mannosyltransferase Deficient Filamentous Fungal Cells and Methods of Use Thereof
#409T cell activating bispecific antigen binding molecules
#410SIALYLATED GLYCOPROTEINS
#411Antibodies that recognize red blood cell antigens
#412ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME
#413Bispecific antibodies against CEACAM5 and CD47
#414Anti-CCR8 monoclonal antibodies and uses thereof
#415PATHOGEN BINDING METHODS AND COMPOSITIONS
#416POTENCY ASSAYS FOR ANTIBODY DRUG SUBSTANCE BINDING TO AN FC RECEPTOR
#417NON-CONSENSUS GLYCOSYLATION OF BISPECIFIC ANTIBODIES
#418MODULATING ANTIBODY EFFECTOR FUNCTIONS
#419High concentration anti-blys pharmaceutical formulations
#420Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)
#421ANTIBODY FOR ENRICHMENT OF CELLS
#422SYSTEM AND METHOD FOR CHARACTERIZING DRUG PRODUCT IMPURITIES
#423Afucosylated Anti-FGFR2IIIB Antibodies
#424DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
#425METHOD FOR THE EXPRESSION OF AN ANTIBODY-MULTIMER-FUSION
#426Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
#427Antibodies specific to glycosylated PD-L1 and methods of use thereof
#428CD25 Antibodies
#429Manufacturing methods for producing anti-TNF antibody compositions
#430Anti-tumor necrosis factor (TNF) antibodies and compositions thereof
#431TREATMENT OF LUNG CANCER USING AN ANTI-FUCOSYL-GM1 ANTIBODY
#432Anti-PD-L1 antibodies and variants
#433ILT7 binding molecules and methods of using the same
#434Nucleic acid molecule encoding, and method of producing, a recombinant anti-tumor necrosis factor (TNF) antibody
#435Methods for increasing mannose content of recombinant proteins
#436Site-specific glycoengineering of targeting moieties
#437CDCP1-TARGETED THERAPIES
#438Antibodies to human complement C2B
#439Anti Human Interleukin-1 Receptor Accessory Protein (IL1 RAP) Antibodies and Uses Thereof
#440MULTIMERIZATION OF IL-15/IL-15R-ALPHA-FC COMPLEXES TO ENHANCE IMMUNOTHERAPY
#441ANTI-OX40 ANTIBODIES AND METHODS OF USE THEREOF
#442AFLIBERCEPT ATTRIBUTES AND METHODS OF CHARACTERIZING AND MODIFYING THEREOF
#443REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXES
#444Site-specific antibody-drug conjugation through glycoengineering
#445Antibodies Directed Against Programmed Death-1 (PD-1)
#446Activatable Anti-CTLA-4 Antibodies and Uses Thereof
#447Manufacturing Methods To Control C-Terminal Lysine, Galactose And Sialic Acid Content In Recombinant Proteins
#448ANTIBODIES THAT TARGET HIV GP120 AND METHODS OF USE
#449GLYCOENGINEERED ANTIBODY DRUG CONJUGATES
#450Methods for increasing mannose content of recombinant proteins
#451CONTROLLED FUCOSYLATION OF ANTIBODIES
#452BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
#453Anti-CD20 antibody
#454NOVEL POLYPEPTIDES
#455ANTI-CD39 ANTIBODIES
#456GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES
#457TETRAVALENT MULTISPECIFIC ANTIBODIES
#458IMMUNOGLOBULIN A ANTIBODIES AND METHODS OF PRODUCTION AND USE
#459CYTOTOXICITY-INDUCING THERAPEUTIC AGENT
#460Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer
#461Combination Therapy for the Treatment of Cancer
#462METHODS OF MODULATING ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
#463Methods of producing ustekinumab
#464BCMA antibodies and use of same to treat cancer and immunological disorders
#465Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR)
#466COMPOUNDS AND METHODS FOR TREATMENT OF HEAD AND NECK CANCER
#467Humanized and affinity-matured anti-CEACAM1 antibodies
#468ANTI-HIV ANTIBODY AND METHOD FOR PRODUCING SAME
#469Compositions and Production of Recombinant AAV Viral Vectors Capable of Glycoengineering In Vivo
#470Bispecific antigen-binding constructs targeting HER2
#471ENGINEERED IGA ANTIBODIES AND METHODS OF USE
#472PRODUCTIVITY-ENHANCED ANTIBODY AND METHOD FOR PRODUCING SAME
#473Novel Rationally Designed Protein Compositions
#474Method for the production of a glycosylated immunoglobulin
#475Engineered IGA antibodies and methods of use
#476DE-ADCC/CDC FUNCTIONS OF ANTIBODIES AND THEIR APPLICATIONS
#477ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES
#478Anti-transthyretin antibodies
#479ANTI-RSPO3 ANTIBODIES AND METHODS OF USE
#480Rat model of IgA nephropathy induced with a multimeric recombinant IgA fragment
#481COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODY
#482ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES
#483Antibodies directed against leukotoxins
#484Methods for site specific conjugation of proteins containing glycosylated Fc domains
#485Engineered antibody Fc variants for enhanced serum half life
#486CMP-dependent sialidase activity
#487MANGANESE SUPPLEMENTATION FOR CONTROL OF GLYCOSYLATION IN MAMMALIAN CELL CULTURE PROCESS
#488FUSION POLYPEPTIDE COMPRISING POLYPEPTIDE REGION THAT CAN BE O-GLYCOSYLATED
#489Anti-CD20 glycoantibodies and uses thereof
#490BISPECIFIC ANTIBODIES AGAINST HER2
#491AFUCOSYLATED ANTIBODIES AND MANUFACTURE THEREOF
#492METHODS OF USING ANTI-TREM2 ANTIBODIES
#493MULTISPECIFIC ANTIBODIES
#494Fusion proteins comprising an anti-CD40 antibody and cancer antigens
#495Isoform-selective anti-TGFβ antibodies and methods of use
#496Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
#497ANTI-CD74 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODIES AND METHODS OF USING ANTI-CD74 ANTIBODIES
#498Sialylated Glycoproteins
#499Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
#500Endo-S2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins
#501Methods of use of CD24 for the prevention and treatment of leukemia relapse
#502METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS
#503Fucosylation-deficient cells
#504COMPOSITIONS AND METHODS FOR PREVENTING OR REVERSING T-CELL EXHAUSTION THROUGH ECTONUCLEOTIDASE INHIBITION AND ANTIBODY-MEDIATED TARGET CYTOSIS
#505Method for the production of a glycosylated immunoglobulin
#506COMBINATION THERAPIES COMPRISING CD137/HER2 BISPECIFIC AGENTS AND PD-1 AXIS INHIBITORS AND USES THEREOF
#507Treatment or prevention of diseases and disorders associated with cells that express IL-6 with Anti-IL-6 antibodies
#508CELL CULTURE STRATEGIES FOR MODULATING PROTEIN GLYCOSYLATION
#509Anti-CCR8 antibodies and uses thereof
#510Human Anti-Tau Antibodies
#511METHODS OF GLYCOPROTEIN ANALYSIS
#512DIMERIC PROTEIN WITH TRIPLE MUTATIONS
#513Immune complex
#514MODULATION OF CELL GROWTH AND GLYCOSYLATION IN RECOMBINANT GLYCOPROTEIN PRODUCTION
#515Anti-MUC1 antibody
#516BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47
#517ANTI-CD73 ANTIBODIES
#518Methods of treating myelodysplastic syndrome and acute myeloid leukemia with nonfucosylated anti-CD70 antibodies
#519ANTI-PDL1 ANTIBODY FORMULATIONS
#520Methods of making fucosylated and afucosylated forms of a protein
#521Anti-OX40 antibodies and methods of use
#522Methods for preparing antibodies with a defined glycosylation pattern
#523Humanized monoclonal advanced glycation end-product antibody
#524Antibody compositions for disrupting biofilms
#525Antibody therapies for human immunodeficiency virus (HIV)
#526PEPTIDIC LINKER WITH REDUCED POST-TRANSLATIONAL MODIFICATION
#527Methods of using bispecific antigen-binding constructs targeting HER2
#528METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING SICKLE-CELL DISEASE
#529Antibody neutralizing human respiratory syncytial virus
#530ANTI-MUC1 ANTIBODY-DRUG CONJUGATE
#531Lysine conjugated immunoglobulins
#532ANTI-INTERFERON GAMMA ANTIBODIES AND USES THEREOF
#533ANTI-INTERFERON GAMMA ANTIBODIES AND USES THEREOF
#534NOVEL ANTIBODY FORMAT
#535COMBINATION OF ANTI-CD20 ANTIBODY, P13 KINASE-DELTA SELECTIVE INHIBITOR, AND BTK INHIBITOR TO TREAT B-CELL PROLIFERATIVE DISORDERS
#536Methods for increasing mannose content of recombinant proteins
#537Modified antibody, antibody-conjugate and process for the preparation thereof
#538MODULATING ANTIBODY DEPENDENT CELLULAR PHAGOCYTOSIS
#539Human immunodeficiency virus neutralizing antibodies
#540METHOD FOR CONTROLLING THE AFUCOSYLATION LEVEL OF A GLYCOPROTEIN COMPOSITION
#541FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION
#542Methods of diagnosis and treatment of tuberculosis and infection
#543Protease deficient filamentous fungal cells and methods of use thereof
#544Optimized Fc variants
#545METHODS AND COMPOSITIONS FOR TREATING YELLOW FEVER
#546Interleukin-2 muteins for the expansion of T-regulatory cells
#547Site-specific antibody-drug glyconjugates and methods
#548Anti-inflammatory polypeptides
#549Engineered IGA antibodies and methods of use
#550Transglutaminase conjugation method and linker
#551Transgenic mouse for aglycosylated antibody production and use of aglycosylated antibody produced therefrom
#552Engineered IgA antibodies and methods of use
#553POLYPEPTIDE IMPROVED IN PROTEIN PURITY AND AFFINITY FOR ANTIGEN, CONJUGATE THEREOF WITH ANTIBODY OR ANTIGEN-BINDING FRAGMENT, AND PREPARATION METHOD THEREFOR
#554METHODS OF GLYCOENGINEERING PROTEOGLYCANS WITH DISTINCT GLYCAN STRUCTURES
#555METHODS FOR MODULATING MANNOSE CONTENT OF RECOMBINANT PROTEINS
#556Antibodies that neutralize RSV, MPV and PVM and uses thereof
#557Fusion Protein Constructs Comprising an Anti-MUC1 Antibody and IL-15
#558Catheter package including catheter straightening means
#559Anti-inflammatory polypeptides
#560Anti-TREM1 antibodies and related methods
#561Anti-CXCR5 antibodies and compositions and uses thereof
#562Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
#563Interleukin-2 muteins for the expansion of T-regulatory cells
#564Targeted immunotolerance
#565Antibody glycoconjugates and methods of production and use
#566Methods and materials for treating cancer
#567Humanized antibodies against CD269 (BCMA)
#568TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE
#569ANTIBODY AND PROTEIN FORMULATIONS
#570Combination therapies with anti-CD38 antibodies
#571Compositions and methods for inhibiting pathogen infection
#572Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
#573Anti-CD25 antibody agents
#574FORMULATIONS OF HUMAN ANTI-PD-LI ANTIBODIES
#575Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
#576Engineering pH-dependent antigen binding activity into anti-HIV antibodies with improved pharmacokinetics
#577Fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the Fc-region
#578Anti-CD25 for tumour specific cell depletion
#579Sialylated Glycoproteins
#580Anti-CD25 for tumour specific cell depletion
#581ANTIBODIES TARGETING CD32B AND METHODS OF USE THEREOF
#582L2A5 antibody or functional fragment thereof against tumour antigens
#583Anti-PD-1 antibodies
#584PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN
#585Sialylated Glycoproteins
#586Radiolabeling of polypeptides
#587Anti-CD25 for tumour specific cell depletion
#588Anti-CD25 for tumour specific cell depletion
#589Anti-CD25 for tumour specific cell depletion
#590Anti-CD25 antibody agents
#591PROCESS FOR PRODUCING HU14.18K322A MONOCLONAL ANTIBODY
#592ANTI-PD-1 ANTIBODY COMPOSITIONS
#593Anti-interleukin-33 antibodies and uses thereof
#594Anti-CD25 antibody agents
#595CD73 blockade
#596Anti-CD43 antibody and use thereof for cancer treatment
#597Anti-CDH6 antibody and anti-CDH6 antibody-drug conjugate
#598COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY
#599Cell culture medium
#600Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods